SIGA News and Press, SIGA Technologies Inc. From 09/09/22

On Friday, the National Institutes of Health (NIH) announced the start of a late-stage clinical trial to test Siga Technologies’ ( NASDAQ: SIGA ) Tpoxx antiviral pill on monkeypox patients. Tpoxx, approved in the U.S. for related smallpox infection, is also used to ...

SIGA Technologies (NASDAQ: SIGA) has been one of the hottest stocks on the markets this year. Its monkeypox treatment Tpoxx has led to a spike in revenue, and investors have been optimistic it could generate even better numbers in the future. It has the potential to become the ...

Health officials in Texas confirmed Tuesday the death of a person diagnosed with monkeypox virus in what could be the first fatality linked to the outbreak in the U.S. The adult patient was a severely immunocompromised individual in Harris County, the Texas Department of State Healt...

Meme stocks have been making a resurgence in recent weeks. Bed Bath & Beyond and AMC Entertainment Holdings , for instance, have experienced significant volatility of late, surging in value only to end up crashing. Meme stocks are a bit of a roller coaster for investors, and the...

Chimerix has been a developer of antivirals. Its key antiviral drug, tembexa, got approved last year and is being sold to a third party. The company's pivot to oncology leaves us confused. I covered Chimerix, Inc. ( CMRX ) last year , when it had just transitione...

A team of British scientists, who conducted one of the major trials to find COVID-19 therapies, has launched a new clinical study to evaluate whether the antiviral tecovirimat developed by SIGA Technologies ( NASDAQ: SIGA ) is effective against monkeypox. The scientists fr...

At the start of 2020, Moderna had a market capitalization of around $6.5 billion. Today, it's worth close to 10 times that amount. It has been a 10-bagger investment within just a few years, thanks to its COVID-19 vaccine. One company that investors may be hoping to follow in it...

The Biden administration Thursday said it is making available 50K treatment courses of SIGA Technologies' Tpoxx (tecovirimat) to jurisdictions next week. The antiviral is approved for treatment of smallpox, but can also be used for monkeypox under the US FDA's Expanded Access ...

SIGA Technologies ( NASDAQ: SIGA ), the maker of smallpox therapy TPOXX, plans to start clinical trials for its lead product, activating trial sites in the U.K. for the first-time next week to evaluate the treatment against the related monkeypox virus Bloomberg reported Wednes...

Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as p...